The University of Chicago Header Logo

Connection

James Vardiman to Leukemia, Myeloid

Back to Details
This is a "connection" page, showing publications James Vardiman has written about Leukemia, Myeloid.
James Vardiman
Connection Strength
1.132
Leukemia, Myeloid
  1. The new World Health Organization classification of myeloid neoplasms: Q&A with James W. Vardiman, MD. Clin Adv Hematol Oncol. 2003 Jan; 1(1):18, 21.
    View in: PubMed
    Score: 0.194
  2. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016 05 19; 127(20):2391-405.
    View in: PubMed
    Score: 0.121
  3. Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant. Am J Clin Pathol. 2007 Feb; 127(2):197-205.
    View in: PubMed
    Score: 0.064
  4. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol. 2006 Aug 20; 24(24):3904-11.
    View in: PubMed
    Score: 0.062
  5. Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study. Blood. 2006 Sep 01; 108(5):1677-83.
    View in: PubMed
    Score: 0.061
  6. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood. 2006 Jul 01; 108(1):63-73.
    View in: PubMed
    Score: 0.060
  7. Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. J Clin Oncol. 2005 Dec 20; 23(36):9234-42.
    View in: PubMed
    Score: 0.059
  8. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol. 2005 Aug 20; 23(24):5705-17.
    View in: PubMed
    Score: 0.058
  9. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study. J Clin Oncol. 2005 Jan 20; 23(3):482-93.
    View in: PubMed
    Score: 0.055
  10. Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621. J Clin Oncol. 2004 Nov 01; 22(21):4290-301.
    View in: PubMed
    Score: 0.055
  11. Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia. Blood. 2004 Jun 01; 103(11):4036-42.
    View in: PubMed
    Score: 0.052
  12. BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study. Blood. 2003 Sep 01; 102(5):1613-8.
    View in: PubMed
    Score: 0.050
  13. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood. 2003 Jul 01; 102(1):43-52.
    View in: PubMed
    Score: 0.049
  14. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res. 2001 Oct 01; 61(19):7233-9.
    View in: PubMed
    Score: 0.044
  15. Myeloid leukemia after hematotoxins. Environ Health Perspect. 1996 Dec; 104 Suppl 6:1303-7.
    View in: PubMed
    Score: 0.032
  16. Haematopoietic malignancies in zoo animals. J Comp Pathol. 1992 Jan; 106(1):15-24.
    View in: PubMed
    Score: 0.023
  17. t(3;21)(q26;q22): a recurring chromosomal abnormality in therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood. 1990 Dec 15; 76(12):2594-8.
    View in: PubMed
    Score: 0.021
  18. Philadelphia chromosome-negative chronic myelogenous leukaemia: a morphological reassessment. Br J Haematol. 1985 Jul; 60(3):457-67.
    View in: PubMed
    Score: 0.014
  19. Acute panmyelosis with myelofibrosis: a clinicopathological study on 46 patients including histochemistry of bone marrow biopsies and follow-up. Ann Hematol. 2004 Aug; 83(8):513-21.
    View in: PubMed
    Score: 0.013
  20. Morphologic and cytochemical observations on the overt leukemic phase of therapy-related leukemia. Am J Clin Pathol. 1983 May; 79(5):525-30.
    View in: PubMed
    Score: 0.012
  21. Evolution of karyotypes in Philadelphia (Ph1) chromosome-negative chronic myelogenous leukemia. Cancer. 1979 Feb; 43(2):411-6.
    View in: PubMed
    Score: 0.009
  22. Correlation of clinical findings with quinacrine-banded chromosomes in 90 adults with acute nonlymphocytic leukemia: an eight-year study (1970-1977). N Engl J Med. 1978 Sep 21; 299(12):613-9.
    View in: PubMed
    Score: 0.009
  23. Partial deletion of long arm of chromosome 17: a specific abnormality in acute promyelocytic leukemia? Arch Intern Med. 1976 Jul; 136(7):825-8.
    View in: PubMed
    Score: 0.008
  24. Ultrastructural characterization of de novo and secondary leukemias. Virchows Arch B Cell Pathol Incl Mol Pathol. 1982; 39(3):239-57.
    View in: PubMed
    Score: 0.003
  25. Dysmyelopoietic syndrome: sequential clinical and cytogenetic studies. Blood. 1980 Apr; 55(4):636-44.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.